{"ranked_hypotheses":[{"title":"GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease","description":"Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and promotes alpha-synuclein accumulation through a feed-forward lysosomal stress loop. The most actionable therapeutic strategy is GCase restoration or substrate correction in genotype-enriched GBA1-PD rather than broad TFEB activation alone.","target_gene":"GBA1","dimension_scores":{"evidence_strength":0.86,"novelty":0.48,"feasibility":0.82,"therapeutic_potential":0.84,"mechanistic_plausibility":0.86,"druggability":0.86,"safety_profile":0.68,"competitive_landscape":0.58,"data_availability":0.86,"reproducibility":0.78},"composite_score":0.76,"evidence_for":[{"claim":"GBA1 mutations strongly increase Parkinson's disease risk and support a causal genetic entry point.","pmid":"19690987"},{"claim":"GCase activity is reduced in Parkinson's substantia nigra, supporting lysosomal convergence beyond inherited GBA1 variants.","pmid":"23685549"},{"claim":"Alpha-synuclein can inhibit GCase, supporting a bidirectional pathological loop.","pmid":"21799912"}],"evidence_against":[{"claim":"Reduced GCase activity in sporadic disease may be secondary to neurodegeneration or alpha-synuclein burden rather than the initiating cause.","pmid":"23034917"},{"claim":"Broad TFEB activation may rescue lysosomal stress without proving the GBA1-alpha-synuclein loop is the dominant therapeutic node.","pmid":"25801896"}]},{"title":"C9orf72 repeat RNA and dipeptide-repeat toxicity in ALS/FTD","description":"C9orf72 hexanucleotide repeat expansion produces repeat RNA foci and RAN-translated dipeptide-repeat proteins that disrupt nucleocytoplasmic transport, translation, stress granules, and neuronal survival. The strongest program should not be DPR-only; it should separately interrogate sense RNA, antisense RNA, DPRs, and C9orf72 haploinsufficiency.","target_gene":"C9orf72","dimension_scores":{"evidence_strength":0.82,"novelty":0.62,"feasibility":0.66,"therapeutic_potential":0.78,"mechanistic_plausibility":0.84,"druggability":0.74,"safety_profile":0.56,"competitive_landscape":0.50,"data_availability":0.80,"reproducibility":0.72},"composite_score":0.70,"evidence_for":[{"claim":"C9orf72 repeat expansion is the most common genetic cause of ALS/FTD.","pmid":"21944778"},{"claim":"Dipeptide-repeat proteins accumulate in patient neurons and are linked to pathology.","pmid":"25437307"},{"claim":"Poly-GR and poly-PR disrupt nuclear import in model systems.","pmid":"26138283"},{"claim":"Antisense oligonucleotide reduction of repeat products improves phenotypes in preclinical models.","pmid":"25907378"}],"evidence_against":[{"claim":"DPR reduction alone may be insufficient, as BIIB078 reduced target biomarkers without clinical benefit.","pmid":"NA"},{"claim":"Persistent CNS pathologies after target engagement weaken a simple DPR-only therapeutic model.","pmid":"40865525"}]},{"title":"Mitophagy and NAD pathway enhancement in sporadic Parkinson's disease","description":"Sporadic Parkinson's disease may involve impaired mitochondrial quality control, and NAD augmentation or other mitophagy-promoting strategies could protect dopaminergic neurons. The key requirement is direct proof of mitophagy flux in vulnerable human dopaminergic neurons and disease-relevant alpha-synuclein models.","target_gene":"PINK1; PRKN","dimension_scores":{"evidence_strength":0.66,"novelty":0.50,"feasibility":0.76,"therapeutic_potential":0.68,"mechanistic_plausibility":0.74,"druggability":0.78,"safety_profile":0.70,"competitive_landscape":0.56,"data_availability":0.68,"reproducibility":0.62},"composite_score":0.67,"evidence_for":[{"claim":"PINK1 mutations cause familial Parkinson's disease, validating mitophagy biology.","pmid":"15133518"},{"claim":"PRKN mutations cause familial Parkinson's disease, supporting mitochondrial quality control as a disease pathway.","pmid":"14695260"},{"claim":"Mitophagy is impaired in sporadic Parkinson's patient fibroblasts.","pmid":"25019414"},{"claim":"NAD precursors can enhance mitophagy and protect dopaminergic neurons in models.","pmid":"29420476"}],"evidence_against":[{"claim":"PINK1 knockout mice often show weak or late dopaminergic degeneration, limiting translational confidence.","pmid":"NA"},{"claim":"Nicotinamide riboside alters NAD metabolism broadly, so benefit would not necessarily prove mitophagy as the operative mechanism.","pmid":"NA"}]},{"title":"TDP-43 LLPS and proteostasis dysregulation in ALS/FTD","description":"TDP-43 stress-granule entry and liquid-liquid phase separation may transition from reversible condensates into pathological aggregates when chaperone disassembly and post-translational regulation fail. The therapeutic opportunity is biologically compelling but not yet product-shaped; success requires restoring nuclear TDP-43 function and RNA-splicing integrity, not only dissolving inclusions.","target_gene":"TARDBP","dimension_scores":{"evidence_strength":0.70,"novelty":0.66,"feasibility":0.46,"therapeutic_potential":0.66,"mechanistic_plausibility":0.76,"druggability":0.42,"safety_profile":0.48,"competitive_landscape":0.60,"data_availability":0.72,"reproducibility":0.58},"composite_score":0.60,"evidence_for":[{"claim":"TDP-43 forms stress granules through LLPS under physiological stress conditions.","pmid":"24670997"},{"claim":"Pathological TDP-43 aggregates colocalize with stress-granule markers in ALS tissue.","pmid":"28661562"},{"claim":"TARDBP mutations cause familial ALS, confirming disease relevance.","pmid":"19479373"},{"claim":"TDP-43 frameshift mutations alter LLPS behavior.","pmid":"31853077"}],"evidence_against":[{"claim":"LLPS-to-aggregation is plausible but not therapeutically settled, and inclusions may be downstream of broader nuclear loss-of-function and proteostasis failure.","pmid":"38029395"},{"claim":"Stress-granule colocalization does not prove stress granules seed disease in vivo.","pmid":"NA"}]},{"title":"TREM2-SYK microglial activation as a stage-specific Alzheimer's disease modifier","description":"TREM2-SYK signaling controls microglial survival, plaque association, phagocytosis, and disease-associated microglial state transitions. The biology remains strong, but standalone TREM2 agonism in broad early Alzheimer's disease is weakened by recent clinical failure; future use should be stage-specific, biomarker-enriched, or combined with amyloid or tau-directed therapy.","target_gene":"TREM2; SYK","dimension_scores":{"evidence_strength":0.72,"novelty":0.50,"feasibility":0.58,"therapeutic_potential":0.56,"mechanistic_plausibility":0.78,"druggability":0.74,"safety_profile":0.42,"competitive_landscape":0.40,"data_availability":0.78,"reproducibility":0.62},"composite_score":0.61,"evidence_for":[{"claim":"TREM2 R47H increases Alzheimer's disease risk, supporting human genetic relevance.","pmid":"22577221"},{"claim":"Trem2 knockout worsens plaque-associated microglial dysfunction in 5xFAD mice.","pmid":"26621723"},{"claim":"TREM2 agonistic antibodies enhance microglial plaque response in models.","pmid":"30509931"},{"claim":"SYK is required for downstream TREM2 signaling.","pmid":"26178167"}],"evidence_against":[{"claim":"TREM2 agonism can improve plaque-related microglial metrics without necessarily improving cognition or downstream neurodegeneration.","pmid":"NA"},{"claim":"The AL002 phase 2 trial showed target engagement but missed the primary clinical endpoint, weakening monotherapy feasibility.","pmid":"NA"}]},{"title":"Astrocyte senescence and SASP-driven neuroinflammation in ALS","description":"ALS astrocytes may acquire p16/p21-positive senescence-like states and release SASP factors that activate microglia and accelerate motor-neuron loss. This remains a discovery-stage hypothesis because senescence markers may reflect reactive astrocytosis, aging, or terminal inflammation rather than a primary causal driver.","target_gene":"CDKN2A; CDKN1A; IL6","dimension_scores":{"evidence_strength":0.50,"novelty":0.62,"feasibility":0.46,"therapeutic_potential":0.54,"mechanistic_plausibility":0.58,"druggability":0.50,"safety_profile":0.34,"competitive_landscape":0.66,"data_availability":0.52,"reproducibility":0.42},"composite_score":0.51,"evidence_for":[{"claim":"Astrocytes in SOD1G93A mice and ALS patients show senescence markers.","pmid":"29937267"},{"claim":"SASP-associated inflammatory factors are elevated in ALS CSF and post-mortem tissue.","pmid":"32572062"},{"claim":"Young astrocytes can rescue motor-neuron survival in co-culture, supporting astrocyte contribution to motor-neuron vulnerability.","pmid":"25437563"}],"evidence_against":[{"claim":"SASP cytokines are not cell-source-specific and do not prove astrocyte senescence precedes neurodegeneration.","pmid":"NA"},{"claim":"Systemic senolytics have broad off-target immune, vascular, platelet, and CNS-penetrance concerns.","pmid":"29100065"}]},{"title":"Tau propagation through muscarinic receptor-mediated BBB transcytosis","description":"The hypothesis proposes that pathological tau enters or spreads through the CNS via M1/M3 muscarinic receptor-mediated BBB transcytosis, with LRP1 and other uptake pathways contributing. This is the least development-ready program because LRP1-mediated tau uptake is credible but the muscarinic BBB mechanism remains speculative and experimentally under-tested.","target_gene":"CHRM1; CHRM3; LRP1","dimension_scores":{"evidence_strength":0.34,"novelty":0.74,"feasibility":0.30,"therapeutic_potential":0.32,"mechanistic_plausibility":0.38,"druggability":0.28,"safety_profile":0.24,"competitive_landscape":0.68,"data_availability":0.40,"reproducibility":0.30},"composite_score":0.40,"evidence_for":[{"claim":"LRP1 mediates neuronal tau uptake and trans-synaptic spread.","pmid":"29847938"},{"claim":"Peripheral tau is detectable in Alzheimer's disease and correlates with CNS pathology measures.","pmid":"26159303"},{"claim":"Muscarinic receptors can regulate tau secretion in cellular models.","pmid":"32084339"}],"evidence_against":[{"claim":"LRP1 and neuronal-network propagation are more established explanations than M1/M3-mediated BBB transcytosis.","pmid":"32296178"},{"claim":"The proposed intracerebral tau-seeding experiment would not directly test peripheral-to-CNS BBB transcytosis.","pmid":"NA"},{"claim":"CHRM1/CHRM3 perturbation would create major cognitive, autonomic, vascular, and BBB confounds.","pmid":"NA"}]}],"knowledge_edges":[{"source_id":"GBA1_GCase_PD_hypothesis","source_type":"hypothesis","target_id":"GBA1","target_type":"gene","relation":"targets"},{"source_id":"GBA1_GCase_PD_hypothesis","source_type":"hypothesis","target_id":"SNCA","target_type":"gene","relation":"modulates_pathology_of"},{"source_id":"GBA1_GCase_PD_hypothesis","source_type":"hypothesis","target_id":"lysosome","target_type":"pathway","relation":"acts_through"},{"source_id":"C9orf72_RNA_DPR_hypothesis","source_type":"hypothesis","target_id":"C9orf72","target_type":"gene","relation":"targets"},{"source_id":"C9orf72_RNA_DPR_hypothesis","source_type":"hypothesis","target_id":"RAN_translation","target_type":"pathway","relation":"acts_through"},{"source_id":"C9orf72_RNA_DPR_hypothesis","source_type":"hypothesis","target_id":"nucleocytoplasmic_transport","target_type":"pathway","relation":"disrupts"},{"source_id":"mitophagy_NAD_PD_hypothesis","source_type":"hypothesis","target_id":"PINK1","target_type":"gene","relation":"targets_pathway"},{"source_id":"mitophagy_NAD_PD_hypothesis","source_type":"hypothesis","target_id":"PRKN","target_type":"gene","relation":"targets_pathway"},{"source_id":"mitophagy_NAD_PD_hypothesis","source_type":"hypothesis","target_id":"mitophagy","target_type":"pathway","relation":"enhances"},{"source_id":"TDP43_LLPS_ALS_FTD_hypothesis","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"targets"},{"source_id":"TDP43_LLPS_ALS_FTD_hypothesis","source_type":"hypothesis","target_id":"stress_granule_LLPS","target_type":"pathway","relation":"modulates"},{"source_id":"TREM2_SYK_AD_hypothesis","source_type":"hypothesis","target_id":"TREM2","target_type":"gene","relation":"targets"},{"source_id":"TREM2_SYK_AD_hypothesis","source_type":"hypothesis","target_id":"SYK","target_type":"gene","relation":"signals_through"},{"source_id":"TREM2_SYK_AD_hypothesis","source_type":"hypothesis","target_id":"disease_associated_microglia","target_type":"cell_state","relation":"promotes_transition_to"},{"source_id":"astrocyte_senescence_ALS_hypothesis","source_type":"hypothesis","target_id":"CDKN2A","target_type":"gene","relation":"uses_marker"},{"source_id":"astrocyte_senescence_ALS_hypothesis","source_type":"hypothesis","target_id":"CDKN1A","target_type":"gene","relation":"uses_marker"},{"source_id":"astrocyte_senescence_ALS_hypothesis","source_type":"hypothesis","target_id":"IL6_STAT3","target_type":"pathway","relation":"acts_through"},{"source_id":"tau_muscarinic_BBB_hypothesis","source_type":"hypothesis","target_id":"CHRM1","target_type":"gene","relation":"targets"},{"source_id":"tau_muscarinic_BBB_hypothesis","source_type":"hypothesis","target_id":"CHRM3","target_type":"gene","relation":"targets"},{"source_id":"tau_muscarinic_BBB_hypothesis","source_type":"hypothesis","target_id":"LRP1","target_type":"gene","relation":"alternative_or_parallel_tau_uptake_pathway"}],"synthesis_summary":"The debate converges on GBA1/GCase and C9orf72 RNA/DPR biology as the highest-priority therapeutic hypotheses. GBA1 has the best balance of genetic evidence, druggability, biomarkers, and clinical feasibility, while C9orf72 remains mechanistically strong but must be redesigned beyond DPR lowering alone because prior biomarker-positive programs did not translate clinically.\n\nMitophagy/NAD in Parkinson's disease is trialable but mechanistically diffuse, and TDP-43 LLPS remains compelling discovery biology without a clean therapeutic modality. TREM2-SYK should be repositioned toward responder-enriched or combination strategies after AL002 weakened the monotherapy case, whereas astrocyte senescence in ALS and tau muscarinic BBB transcytosis need causal validation before development spending."}